ceftazidime/tazobactam / Generic mfg. - LARVOL DELTA

Susceptibility Studies of Novel Antimicrobial Drugs Against Carbapenem-Resistant and Hypervirulent Klebsiella pneumoniae. (PubMed, J Evid Based Med) - "Cefiderocol appears highly promising as a therapy for CR-hvKP infections. Our findings will not only effectively address the challenge of CR-hvKP resistance, but also provide evidence to support the optimization of clinical therapeutic strategies and further promote the development and application of novel antimicrobial drugs."

Journal • Infectious Disease • Pneumonia

Comprehensive analysis of extensive drug-resistant Salmonella Typhi in Gujarat region, India: genomic findings and prospective alternative therapy. (PubMed, Microbiol Spectr) - "The study discovered notable levels of antibiotic resistance, specifically to cefuroxime (97.54%), doxycycline (97.54%), ceftriaxone (95.90%), cotrimoxazole (95.90%), ampicillin/sulbactam (95.90%), cefotaxime (94.26%), and ciprofloxacin (94.26%)...The combination therapy of β-lactam/β-lactamase inhibitors (BL/BLI) demonstrated good outcomes, with low MICs (<0.5 µg/mL) of ceftazidime/tazobactam, cefixime/tazobactam, and ceftriaxone/tazobactam effective against highly resistant S. Typhi...Our study highlights the possibility of rapid dissemination of antibiotic resistance due to chromosomal point mutations and plasmid-mediated gene transfer. The effectiveness of β-lactam/β-lactamase inhibitors in handling XDR S. Typhi suggests a plausible strategy for treatment that may be included among clinical guidelines."

Journal • Gene Therapies • Infectious Disease

Bloodstream Infections Due to Wild-Type Pseudomonas aeruginosa: Carbapenems and Ceftazidime/Avibactam Prescription Rate and Impact on Outcomes. (PubMed, Infect Dis Rep) - "Both all-cause and BSI-related mortality were comparable between the two groups. Treatment with carbapenem or ceftazidime/avibactam did not represent a protective factor for mortality in wild-type P. aeruginosa BSI."

Journal • Infectious Disease

In vitro antimicrobial activity of the novel antimicrobial peptide OMN-51 against multidrug-resistant Pseudomonas aeruginosa isolated from people with cystic fibrosis (NACFC 2024) - "OAMP, OMN-51 antimicrobial peptide; ND, no data, MDR; multidrug resistant; ATM, aztreonam; FDC, cefiderocol; CAZ, ceftazidime; CZA, ceftazidime-avibactam; CT, ceftazidime-tazobactam; CIP, ciprofloxacin; IPM, imipenem; MEM, meropenem; OFL, ofloxacin; PIP, piperacillin; TZP, piperacillin-tazobactam; TOB, tobramycin. The in vitro findings in this study provide proof of concept that OMN-51 exerts efficient antimicrobial activity against MDR P. aeruginosa in clinical isolates from sputum cultures of PwCF. OMN-51 is a beta-hairpin antimicrobial peptide derived from the innate immune system of Capitella teleta (a marine polychaeta) that selectively disrupts the bacterial membrane, exerting a bactericidal effect on target bacteria. OMN-51 compromises the integrity of the bacterial outer membranes, leading to proton gradient depletion and bacterial cell lysis, followed by rapid bacterial death."

Preclinical • Bronchiectasis • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens. (PubMed, Front Cell Infect Microbiol) - "Carbapenems, tigecycline, and colistin are the last resource antibiotics currently used; however, multiple reports of resistance to these antimicrobial agents have been documented worldwide. Recently, new antibiotics have been evaluated against Gram-negatives, including plazomicin (a new aminoglycoside) to treat CRE infection, eravacycline (a novel tetracycline) with in vitro activity against CRAB, and cefiderocol (a synthetic conjugate) for the treatment of nosocomial pneumonia by carbapenem-non-susceptible Gram-negative isolates. Furthermore, combinations of known β-lactams with recently developed β-lactam inhibitors, such as ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime-tazobactam, and meropenem-vaborbactam, has been suggested for the treatment of infections by extended-spectrum β-lactamases, carbapenemases, and AmpC producer bacteria. Nonetheless, they are not active against all carbapenemases, and there are reports of resistance to these combinations in..."

Journal • Preclinical • Review • Infectious Disease • Pneumonia • Respiratory Diseases

Construction of bacterial consortium for efficient degradation of mixed pharmaceutical dyes. (PubMed, Environ Sci Pollut Res Int) - "The cell wall structure, carbohydrate utilization profile, and metabolic characterization were conducted on the selected strains of C1. Among the 25 different antibiotics, DY7 and DY11 exhibited the highest zone of growth inhibition in the presence of cefixime, and DY10 was restricted by chloramphenicol whereas DY18 was found sensitive to ceftazidime/tazobactam."

Journal

Clinico-bacteriological and antibiotic drug resistance profile of chronic suppurative otitis media at a tertiary care hospital in Western Rajasthan. (PubMed, J Family Med Prim Care) - "showed high sensitivity to colistin, piperacillin-tazobactam, ceftazidime-tazobactam and good sensitivity for cefepime and amikacin; 33.3% S. aureus isolates were Methicillin-resistant which was sensitive to gentamicin, vancomycin and linezolid. Knowledge of the spectrum of microorganisms causing ear discharge is important for effective treatment."

Clinical • Journal • Immunology • Infectious Disease • Otorhinolaryngology

β-Lactams modulate neutrophil extracellular traps formation mediated by mTOR signaling pathway. (PubMed, Biochem Biophys Res Commun) - "We firstly demonstrate that β-Lactams showed the definitive immunomodulation effects through modulating NETs formation, which is depended on PKC-Akt-mTOR signal pathway."

Journal • Immune Modulation • Immunology • Infectious Disease • Inflammation • Septic Shock

Use of Ceftazidime-Avibactam and Ceftolozane-Tazobactam After Lung Transplantation. (PubMed, Transplant Proc) - "CEF-AVI and CEFT-TAZ seems to be effective in treatment of infections caused by MDR bacteria after lung transplant."

Journal